Gastric cancer: Decreasing incidence but stable survival in the Netherlands

Dassen, Anneriet E.; Dikken, Johan L.; Bosscha, K.; Wouters, Michel W. J. M.; Cats, Annemieke; Velde, Cornelis J.H. van de; Coebergh, Jan Willem; Lemmens, Valery

doi:10.3109/0284186x.2013.789139

Cited by 41 publications

(38 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[3][4][5][6][7] Like in other western countries, the incidence of non-cardia gastric cancer in the Netherlands has declined markedly during the last century. 8 The annual incidence has declined from 1950 cases in 1990 to 1435 cases in 2014, which accounts for 1.5% of all new cancer cases. 9…”

Section: Introductionmentioning

confidence: 99%

Accuracy of Hereditary Diffuse Gastric Cancer Testing Criteria and Outcomes in Patients With a Germline Mutation in CDH1

et al. 2015

Self Cite

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Accuracy of Hereditary Diffuse Gastric Cancer Testing Criteria and Outcomes in Patients With a Germline Mutation in CDH1

et al. 2015

Self Cite

View full text Add to dashboard Cite

“…Currently, first-line systemic treatment usually comprises a fluoropyrimidine and a platinum compound with the addition of trastuzumab in the case of human epidermal growth factor receptor 2 (HER2) overexpression, providing a survival benefit up to 9 months compared to no systemic treatment. 1,2,[16][17][18] Current practice is based on the results of several randomized controlled trials. 6,14,15 Because of the lack of consensus on optimal palliative systemic treatment, making choices about the best approach for these patients is challenging, which can result in interhospital and interphysician variation in individual systemic treatment.…”

Section: Introductionmentioning

confidence: 99%

Heterogeneity of first‐line palliative systemic treatment in synchronous metastatic esophagogastric cancer patients: A real‐world evidence study

Dijksterhuis

Verhoeven

Slingerland

et al. 2019

Intl Journal of Cancer

View full text Add to dashboard Cite

The optimal first‐line palliative systemic treatment strategy for metastatic esophagogastric cancer is not well defined. The aim of our study was to explore real‐world use of first‐line systemic treatment in esophagogastric cancer and assess the effect of treatment strategy on overall survival (OS), time to failure (TTF) of first‐line treatment and toxicity. We selected synchronous metastatic esophagogastric cancer patients treated with systemic therapy (2010–2016) from the nationwide Netherlands Cancer Registry (n = 2,204). Systemic treatment strategies were divided into monotherapy, doublet and triplet chemotherapy, and trastuzumab‐containing regimens. Data on OS were available for all patients, on TTF for patients diagnosed from 2010 to 2015 (n = 1,700), and on toxicity for patients diagnosed from 2010 to 2014 (n = 1,221). OS and TTF were analyzed using multivariable Cox regression, with adjustment for relevant tumor and patient characteristics. Up to 45 different systemic treatment regimens were found to be administered, with a median TTF of 4.6 and OS of 7.5 months. Most patients (45%) were treated with doublet chemotherapy; 34% received triplets, 10% monotherapy and 10% a trastuzumab‐containing regimen. The highest median OS was found in patients receiving a trastuzumab‐containing regimen (11.9 months). Triplet chemotherapy showed equal survival rates compared to doublets (OS: HR 0.92, 95%CI 0.83–1.02; TTF: HR 0.92, 95%CI 0.82–1.04) but significantly more grade 3–5 toxicity than doublets (33% vs. 21%, respectively). In conclusion, heterogeneity of first‐line palliative systemic treatment in metastatic esophagogastric cancer patients is striking. Based on our data, doublet chemotherapy is the preferred treatment strategy because of similar survival and less toxicity compared to triplets.

show abstract

“…In the previously mentioned French study, the global prognosis of GC did not improve significantly over a 12-year period of observation [32] . Recent studies from the Netherlands have also confirmed the decreasing incidence of GC but stable survival rates over time [34] . These data seem to be consistent with the findings of a previous GIRCG study: along with the decreasing number of distal IT tumors and the relative increase of DT forms with time, a lack of improvement of cancerrelated survival probability, and a significant increase of peritoneal recurrence after surgery were observed [9] .…”

Section: Changing Epidemiology Of Gastric Cancermentioning

confidence: 79%

Multimodal treatment of gastric cancer in the west: Where are we going?

Marrelli

Połom

Manzoni

et al. 2015

WJG

View full text Add to dashboard Cite

The incidence of gastric cancer (GC) is decreasing worldwide, especially for intestinal histotype of the distal third of the stomach. On the contrary, proximal location and diffuse Lauren histotype have been reported to be generally stable over time. In the west, no clear improvement in long-term results was observed in clinical and population-based studies. Results of treatment in these neoplasms are strictly dependent on tumor stage. Adequate surgery and extended lymphadenectomy are associated with good long-term outcome in early-stage cancer; however, results are still unsatisfactory for advanced stages (Ⅲ and Ⅳ), for which additional treatments could provide a survival benefit. This implies a tailored approach to GC. The aim of this review was to summarize the main multimodal treatment options in advanced resectable GC. Perioperative or postoperative treatments, including chemotherapy, chemoradiotherapy, targeted therapies, and hyperthermic intraperitoneal chemotherapy have been reviewed, and the main ongoing and completed trials have been analyzed. An original tailored multimodal approach to non-cardia GC has been also proposed.

show abstract

Gastric cancer: Decreasing incidence but stable survival in the Netherlands

Cited by 41 publications

References 21 publications

Accuracy of Hereditary Diffuse Gastric Cancer Testing Criteria and Outcomes in Patients With a Germline Mutation in CDH1

Accuracy of Hereditary Diffuse Gastric Cancer Testing Criteria and Outcomes in Patients With a Germline Mutation in CDH1

Heterogeneity of first‐line palliative systemic treatment in synchronous metastatic esophagogastric cancer patients: A real‐world evidence study

Multimodal treatment of gastric cancer in the west: Where are we going?

Contact Info

Product

Resources

About